A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People >/= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection,
Role: Investigational Pharmacist,
Gilead Sciences, Inc,
(07/2024 - 07/2025)
Status: Approved
A Phase I, Randomized, Open-Label, Active Controlled, Multi-Center Pilot Study to Compare Reference to Reference Pharmacodynamics of BOTOX® (onabotulinumtoxinA) in Healthy Subjects. Protocol: MR 103A-0I-IPS-1001. lnformed Consent Form Version Dated 25 November 2022.,
Role: Investigational Pharmacist,
Mylan Pharmaceuticals,
(11/2023 - 03/2024)
Status: Completed
Effectiveness of semaglutide 2.4 mg vs. commercially available medications for chronic weight management in participants with obesity in a multi-employer setting in the US – a pragmatic clinical study (POSEY),
Role: Research Coordinator/Nurse,
Novo Nordisk Pharmaceuticals Inc.,
(10/2022)
Status: Approved
Use of the Guardian™ Connect system with Smart Connected Devices: CIP 331,
Role: Research Coordinator/Nurse,
Medtronic, Inc.,
Status: Completed
ABC [Afrezza with Basal Combination]: A Phase 4 Study of Mealtime Control with Afrezza in Adult Subjects with Type I Diabetes Mellitus in Combination with an Automated Insulin Pump or Insulin Degludec,
Role: Investigator,
MannKind Corporation,
Status: Completed
INHALE-3: A 17-Week Randomized Trial and a 13-Week Extension, Evaluating the Efficacy and Safety of Inhaled Insulin (Afrezza® ) Combined with Insulin Degludec Versus Usual Care in Adults with Type 1 Diabetes,
Role: Investigator,
MannKind Corporation,
Status: Completed
IMPACT2: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2 - Evaluation of the AHCL System Insulin-requiring Type 2 Diabetes,
Role: Research Tech/Assistant,
Medtronic, Inc.,
(04/2025)
Status: Completed
Internal
Evaluation of the health and economic outcomes following the integration of a pharmacist managed Diabetes clinic within a primary care setting,
Role: Investigator,
LLU Dept. of Pharmaceutical Sciences,
(02/2022)
Status: Approved